In this study, physicians from the United States evaluated whether response to preoperative chemoradiation predicted survival and recurrence after resection in adenocarcinoma of the distal esophagus.
The team evaluated 366 patients who underwent esophagectomy for adenocarcinoma of the esophagus. Of these, 108 had induction chemoradiation prior to surgery.
The team reviewed the records of these 108 patients.
|22% showed a complete pathologic response.|
|European Journal of Cardiothoracic Surgery|
They found that 22% of resected specimens showed a complete pathologic response (CR), while 78% showed residual tumor (RT).
There was a median 11-month follow-up.
The physicians found that 3-year survival for patients with CR was 64%, compared with 34% in patients with RT.
They calculated that the median survival for patients with CR has not yet been reached, but for those with RT median survival was 19 months.
The team also determined that 3-year cancer-free survival in patients with CR was 57%, compared with 30% in patients with RT.
Again, median cancer-free survival in patients with CR has not been reached, but median cancer-free survival in patients with RT was 9 months.
Dr Jessica Donington's team concluded, "Complete pathologic response to induction chemoradiation is associated with improved early overall and disease-free survival".
"Because recurrent cancer still develops in many of these patients, even after complete pathologic response, the search for the optimal treatment continues".